



**ADVANCES IN CARDIAC  
ARRHYTHMIAS**  
*and*  
**GREAT INNOVATIONS  
IN CARDIOLOGY**

XXIX GIORNATE CARDIOLOGICHE TORINESI

**Directors**  
*Fiorenzo Gaita  
Sebastiano Marra*

**Scientific Committee**  
*Malcolm R. Bell, Usa  
Martin Borggrefe, Germany  
Leonardo Calò, Italy  
Jean François Leclercq, France  
Amir Lerman, Usa  
Dipen Shah, Switzerland*

**Organization Committee**  
*Matteo Anselmino, Italy  
Carlo Budano, Italy  
Davide Castagno, Italy*

**TURIN  
OCTOBER  
27-28,  
2017**  
Centro Congressi  
Unione Industriale  
di Torino

Logo of the Italian Society of Cardiology (Società Italiana di Cardiologia) and the Italian Society of Cardiology (Società Italiana di Cardiologia)

Logo of the University of Turin (Università degli Studi di Torino)

Logo of GVM (Gruppo Vascolare Mediterraneo)

Logo of Maria Pia Hospital

Logo of the Italian Society of Cardiology (Società Italiana di Cardiologia)

Logo of JM (Jornal de Medicina)

# The future of cardiovascular research

Amir Lerman, MD

Barbara Woodward Lips Endowed Professor.  
Director Cardiovascular Research Center  
Mayo Clinic, Rochester, MN



# The future of cardiovascular research

- Past
- Present and immediate future: “wake up call”
- The Future




# The ten advances that have defined modern cardiology

Eugene Braunwald\*

TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA  
Department of Medicine, Harvard Medical School, Boston, MA, USA

## Electrocardiography



## Cholesterol and atherosclerosis

This truly seminal paper led ultimately to the cholesterol theory of atherogenesis, which in turn resulted in successful attempts to lower serum cholesterol in order to reverse, prevent, or at least retard the development of atherosclerosis and its complications.


Anitschkow: Zentralblf. Allg. Pathol. Anat. 1913;24:1

## Cardiac catheterization

First carried out by Forssmann in 1929, a urologist, won the Nobel Prize

## Cardiovascular surgery

The first cardiovascular operation in 1939, ligation of a patent ductus arteriosus in a seven and a half-year old girl



## Coronary angiography and percutaneous coronary angioplasty


In 1958, while performing an angiogram of the aortic root, the tip of the catheter accidentally slipped into the ostium of the right coronary artery.

Sones et al: Circulation 20:773, 1959

## The coronary care unit

In 1961, Desmond Julian, a registrar (fellow/resident) in cardiology at the Royal Infirmary in Edinburgh, wrote a brief paper describing the coronary care unit that was published in Lancet, in which he stated:

## Cardiovascular drugs



## Preventive cardiology

Kannel et al: The Framingham study Ann Intern Med 55:33, 1961

## Cardiac imaging: Echocardiography

During World War II, ultrasound was widely used to detect submarines and to track torpedoes. The collaboration between two brilliant Norwegians, an emeritus Professor of Cardiology, Inge Edler, and an engineer, Helmut Hertz, led to the development of echocardiography. Edler and Hertz: Kungl Fysiogr Sallsk Lund Forth24, 1954

## Cardiac pacemakers and defibrillation

Mirowski et al: N Engl J Med 303:322, 1980




# What Happened Before 2007?

- Facebook didn't exist yet
- Twitter was still a sound
- Cloud was still in the sky
- 4G was a parking space
- “applications” were what you sent to college
- LinkedIn most people thought it was a prison
- Big Data was a good name for a rap star




# The Race Between Human and Technology






# Where are the Future Opportunities in the Cardiovascular Field?

Unmet  
Patients'  
need




Technology



# Where are the Future Opportunities in the Cardiovascular Field?

Unmet  
Patients'  
need



Technology

**Mash up**

a mixture or fusion of disparate elements.

Military Technology  
Academic Centers

# Where are the Future Opportunities in the Cardiovascular Field?

- Precision (Individualized) medicine
- big data analysis
- Remote medicine
- Robotic



# Personalized Medicine: Precision medicine



Will provide the link between an individual's molecular and genetic and clinical profiles

## **Will effect**

Therapy directed to the root cause of the disease will replace treating the symptoms

Pharmaceutical industry


Symptoms

Medical History & Physical  
examination

Presumptive Diagnosis

Treatment based on large  
clinical trials

- **Wrong diagnosis**
- **Net effect of beneficial  
and toxic effects**




# There are several aspects to personalized medicine

Diagnosis

Personalized treatment



Drug toxic but  
beneficial




Drug toxic but  
**not** beneficial

## Patient group



Same diagnosis,  
same prescription



Drug **not** toxic and  
**not** beneficial



Drug **not** toxic  
and beneficial

# Diagnosis

- Affymetrix
- GeneLogic
- Curagen



*The use of of genetic markers to select patients for clinical trials may reduce adverse drug reaction by 10-20%*

Caution: not covered by insurance

No firm data on link to therapy

No firm data from a randomized study on benefit

# Treatment

7/16/2017 KEYTRUDA® (pembrolizumab) | Anti-PD-1 Immunotherapy

KEYTRUDA®  
(pembrolizumab) (12.5% solution)

Financial Assistance | Patient Support | Get Updates | For Health Care Professionals

Important Safety Information  
Medication Guide  
Prescribing Information

LEARN HOW KEYTRUDA CAN HELP FIGHT YOUR CANCER.

## FDA News Release

# FDA approves first cancer treatment for any solid tumor with a specific genetic feature

## For Immediate Release

May 23, 2017

## Release

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

Keytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This indication covers patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and patients with colorectal cancer that has progressed following treatment with certain chemotherapy drugs.



# The number of patients in clinical trials

## PATHOPHYSIOLOGY AND NATURAL HISTORY CORONARY ARTERY DISEASE

1983

**Coronary Artery Surgery Study (CASS): a randomized trial of coronary bypass surgery**  
**Survival data**

CASS PRINCIPAL INVESTIGATORS AND THEIR ASSOCIATES

**ABSTRACT** CASS includes a multicenter patient registry and a randomized controlled clinical trial. It is designed to assess the effect of coronary artery bypass surgery on mortality and selected nonfatal

780  
patients

## Circulation

circ.ahajournals.org

Circulation. 1997;96:2162-2170  
doi: 10.1161/01.CIR.96.7.2162



1829  
patients

## Articles

1997

**Myocardial Infarction and Cardiac Mortality in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial**

## The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

APRIL 12, 2007

VOL. 356 NO. 15

2007

**Optimal Medical Therapy with or without Coronary Intervention for Stable Coronary Disease**

780  
patients

William E. Boden, M.D., Robert A. O'Rourke, M.D., Koon K. Teo, M.B., B.Ch., Paul W. Leung, M.D., Ph.D., David J. Maron, M.D., William J. Kostuk, M.D., Merrill Knudtson, M.D., Marc Dada, M.D., Paul Casperson, Ph.D., Crystal L. Harris, Pharm.D., Bernard R. Chaitman, M.D., Leslee Shaw, Ph.D., Gilbert Gosselin, M.D., Shah Navroz, M.D., Lawrence M. Lide, M.D., Gerald Lau, M.D., Aaron S. Benstein, M.D., David Booth, M.D.

## The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

NOVEMBER 20, 2008

VOL. 359 NO. 21

2008

**Rosuvastatin to Prevent Vascular Events in Men with Elevated C-Reactive Protein**

17,802  
patients

Paul M. Ridker, M.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D.,

## The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

APRIL 8, 2004

VOL. 350 NO. 15

2004

**Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes**

4126  
patients

Christopher P. Cannon, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, M.D., Jean L. Rouleau, M.D., Rene Belder, M.D., Steven V. Joyal, M.D., Karen A. Hill, M.D., and Alan M. Skene, Ph.D., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy in Myocardial Infarction 22 Investigators\*

## The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 13, 2012

VOL. 367 NO. 11

2012

**Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease**

1220  
patients


Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Bindu Kalesan, M.D., Ph.D., Pim A.L. Tonino, M.D., Ph.D., Zsolt Piroth, M.D., Nikola Jagic, M.D., Sven Möbius-Winder, M.D., Ph.D., Nils Witt, M.D., Ph.D., Petr Kala, M.D., Philip McCarthy, M.D., Thomas Engström, M.D., Keith G. Oldroyd, M.D., Kratos Mavroukakis, M.D., Canan Muehler, M.D., Peter Verheij, M.D., Ole Frøbert, M.D., Nick Curzen, B.M., Ph.D.

# Machine Learning

- Used by Amazon, Netflix, Google, Uber to predict consumer behavior
- Capable of analyzing large volumes of data
  - Can identify previously unknown associations
  - Established based on a machine-learning based financial trading company.
- Bring to light “hidden” information within existing medical data. Building decision support tools for personalized risk assessment of life threatening conditions.

# Machine Learning vs Regression Modeling

*Machine learning is data driven rather than hypothesis driven(used by statisticians) potential link between a feature and outcome.*




*This graph represent relationship of 2 parameters but in reality multiple relationships are tested*


# Patient Featurization



**Patient**




**EHR Data**



**Patient  
Feature  
Vector**

# Predictive Models for Multiple Outcomes



- Address multiple types of outcomes and select those that are actionable





# MeScore – a tool for eScreening

Use the results of a **low-cost** and **readily available** blood test to simultaneously calculate risk scores for **multiple types of cancers**



Medscape Medical News > Conference News

## Watson-Powered Diabetes App Predicts Hypoglycemia

Robert Lowes  
January 08, 2016

2 comments

[f](#) [t](#) [+](#) [in](#) [Print](#) [Email](#)

### EDITORS' RECOMMENDATIONS



Real-World Severe Hypoglycemia in Diabetics Exceeds Trial Rates



14 Cancer Centers, IBM Install Supercomputer in Clinic




FDA OKs Insulin Pump With Low-Glucose Suspend Feature

LAS VEGAS — Watson, the IBM supercomputer that won TV's *Jeopardy*, will soon be able to help patients with diabetes prevent hypoglycemia, medical device maker Medtronic announced here at the giant Consumer Technology Association Digital Health Summit.

The company expects to introduce a smartphone app this summer that will provide timely hypoglycemic warnings to patients using its insulin-management devices.

The idea for the app arose from an unpublished study that Medtronic conducted using Watson's "cognitive computing" — buzz words heard commonly at the show. The supercomputer

# Death from Cardiovascular Cause $\leq 180$ Days following PCI



# Electronic Records Implementation

**BestPractice Advisory**

▼ **Advisory - Patient Safety**

**Readmission Risk**

**PROBLEM**

This patient is at high risk for 30 day congestive heart failure readmission after percutaneous coronary intervention.

Average risk for hospital readmission for congestive heart failure is **0.7%**  
This patient's risk is **18.1%**

- Place order: Heart failure nurse home call in 2 days.
- Place order: Social work request for home visiting nurse
- Place order: Cardiology follow up appointment in 5 days

## Perspectives

### Bone Marrow Mononuclear Cell Therapy for Acute Myocardial Infarction

#### A Perspective From the Cardiovascular Cell Therapy Research Network



Robert D. Simari, Carl J. Pepine, Jay H. Traverse, Timothy D. Henry, Roberto Bolli, Daniel B. Spoon, Ed Yeh, Joshua M. Hare, Ivonne Hernandez Schulman, R. David Anderson, Charles Lambert, Shelly L. Sayre, Doris A. Taylor, Ray F. Ebert, Lemuel A. Moyé

**Abstract**—To understand the role of bone marrow mononuclear cells in the treatment of acute myocardial infarction, this overview offers a retrospective examination of strengths and limitations of 3 contemporaneous trials with attention to critical design features and provides an analysis of the combined data set and implications for future directions in cell therapy for acute myocardial infarction. (*Circ Res.* 2014;114:1564-1568.)

Placebo-adjusted Effect Size for  $\Delta$  in LVEF Over Time as a Function


Relationship Between Change in LVEF Over Time and BL EF in TIME

Mash-up: Between different technologies and cells



# Synergy of Device and BioTech

Left Ventricular Assist Device



Beating Heart Cells Created from Stem Cells



***Macrostructure stabilization → Microstructure integration***



# Building your own aortic valve




# Where are the Opportunities in the Medical Field?



- Big data (machine learning)
- Precision (Individualized) medicine
- Remote diagnosis and treatment

# Standardization and equalizing Access to care

## Physician shortage




# Planet of the phones




# The Wearable Decade

...from watches, patches and tattoo's





# Privacy in Healthcare: data security



**63%**



of customers are comfortable with storing their medical records on a cloud

**39%**



don't trust internet sites to keep my health information private and secure

**Information customers are willing to share online**



**25%**

Exercise/  
physical  
activity



**28%**

Weight



**26%**

Sleep patterns



**20%**

Nutritional  
information  
(eg, calories  
consumed, etc)



**25%**

Symptoms/  
general health  
complaints



**15%**


Vital signs (eg,  
blood pressure,  
heart rate, etc)





## Initial Clinical Results Using Intracardiac Electrogram Monitoring to Detect and Alert Patients During Coronary Plaque Rupture and Ischemia

Tim A. Fischell, MD,\* David R. Fischell, PhD,|| Alvaro Avezum, MD,‡ M. Sasha John, PhD,§|| David Holmes, MD,† Malcolm Foster III, MD,¶ Richard Kovach, MD,# Paulo Medeiros, MD,‡

\*Fischell T, Fischell D, Avezum A, John M, Holmes D, Foster M, Kovach R, Medeiros P. Initial clinical results using intracardiac electrogram monitoring to detect and alert patients during coronary plaque rupture and ischemia. J Am Coll Cardiol. 2010;56:14-20.



Intracardiac monitoring was performed in 37 patients at high risk for acute coronary syndromes. The implanted monitor continuously evaluated the patients' ST segments sensed from a conventional pacemaker right ventricle apical lead, and alerted patients to detected ischemic events.





## Using an online, personalized program reduces cardiovascular risk factor profiles in a motivated, adherent population of participants


R. J. Widmer, MD, PhD,<sup>a</sup> Thomas G. Allison, PhD,<sup>a</sup> Brendie Keane, RN,<sup>c</sup> Anthony Dallas, MD,<sup>c</sup> Lilach O. Lerman, MD, PhD,<sup>b</sup> and Amir Lerman, MD<sup>a</sup> Rochester, MN and Nashville, TN

**Methods:** A cohort of employees in Tennessee was subjected to a health risk assessment at baseline. Those who did not meet all 5 healthy benchmarks – body mass index, blood pressure, glucose, total cholesterol and smoking status – were prospectively assigned to a web-based personal health assistant and had repeat measurements taken at 90 days




Schematic displaying the smartphone (B) and online (A) versions of the cardiac rehabilitation program currently being used in a randomized controlled trial.

## Reductions in Raw FRS (left) and Converted FRS 10-year cardiovascular risk percentage (right)






## Percent Change from Baseline in Risk Factors After Completing the Online PHA



# ➡️ **Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial**

William T Abraham, Philip B Adamson, Robert C Bourge, Mark F Aaron, Maria Rosa Costanzo, Lynne W Stevenson, Warren Strickland, Suresh Neelagaru, Nirav Raval, Steven Krueger, Stanislav Weiner, David Shavelle, Bradley Jeffries, Jay S Yadav, for the CHAMPION Trial Study Group\*


Patients with New York Heart Association (NYHA) class III heart failure, a previous hospital admission for heart failure were enrolled in 64 centers in the USA. They were randomly assigned by use of a centralized electronic system to management with a wireless implantable hemodynamic monitoring (W-IHM) system (treatment group) or to a control group for at least 6 months. Only



Number at risk

# “Listening” to our body

It's not what we say, It's HOW we say it



Just Blink: New Device Detects Disease Through Eye Movement



Genetics and epigenetic play a large role in determining face shape,




These figures illustrate representative voice signal characteristics signals from a patient prior and following coronary angiography and intervention as compared to a normal control.

### Average FFT transform of selected voice recording segments

CAD patient  
prior to  
angiography

CAD patient after  
angiography and  
intervention


Example of voice  
signal of a healthy  
individual



Possible acoustic feature related to cardiac condition



# Remote voice recognition of CAD




# Where are the Opportunities in the Medical Field?

- Big data (machine learning)
- Precision (Individualized) medicine
- Remote diagnosis and treatment


# Robotic Revolution; across all industries

## World-wide industrial robot installations



## Automatic Nations

### Top 5 markets for industrial robot sales



Source: International Federation of Robots



We now drive cars, have vision & vacuum robotically...we will not be manually controlling catheters in the future...



# The synchrony of imaging and catheter movement ...practice, plan and perfect...







**CorPath 200 System**


**Control Console**

**Interventional Cockpit**

**Cockpit Monitors (Live/Reference Angio, Hemo)**



# Technology Requirements



Cath lab – at the patient

Immerse IC virtually  
into the cath lab  
Education

# Planning the procedure for the future






Particle therapy for noncancer diseases

Christoph Bert  
GSI Helmholtzzentrum für Schwerionenforschung, Biophysics Department, Planckstraße 1, 64291 Darmstadt, Germany

Rita Engenhardt-Cabillic  
Philipps-University Marburg, Center for Radiology, Department of Radiation Therapy, Baldinger Strasse, 35043 Marburg, Germany

Future treatment by photon beam therapy for atrial fibrillation




A good use of a drone  
Flying ambulance drone to deliver emergency shock





# Pigeons (*Columba livia*) as Trainable Observers of Pathology and Radiology Breast Cancer Images


Pigeons (*Columba livia*) – share many visual system properties with humans – can serve as promising surrogate observers of medical images




The pigeons' training environment

## Generalization from training to test image sets.


After training with differential reinforcement, the birds successfully classified previously unseen breast tissue images in the testing sets, at all magnifications, with no statistically significant decrease in accuracy compared to training-set performance.




## Results of training and testing with mammograms with or without calcifications



## Flock sourcing. Pooling the birds' decisions led to significantly better discrimination



# Robots Threaten These Jobs




Soon you could be competing with a robot for a job.

Economists are sharply divided over the exact timing of the threat from robots and other forms of futuristic technology. Some see an imminent threat, others believe it won't happen until later this century – If at all.


- 1. Toll booth operators and cashiers:** People who work in the transactional space shouldn't be big fans of the Apple Watch or Apple Pay.
- 2. Marketers:** Powerful advertising tools of the future may allow brands to fashion their messages to customers with precision accuracy.
- 3. Interventional cardiologists and radiologists??**

# Comparison of Changes in SBP at 6 Months in 3 Trials of Renal Denervation




Pocock and Gersh: JACC, 2014

# The Natural History of Evolving Therapies



# The future is here: *Fantastic Voyage* 1966



## Conservative Management medical therapies

↓ LDL

↑ HDL

↓ Inflammation

↓ Angiogenesis

↓ Thrombosis



Synthetic HDL



Drug Delivery




Medical  
therapy



Heat-induced  
Ablation

Management  
of CAD


## Invasive Management revascularization



PCI




Drug Delivery



Endothelial Cell  
Recruitment

↓ Restenosis

↑ Endothelialization



CABG




Tissue Engineered  
Vascular Graft

↑ Graft success



# Investigative Pathways Leading from Gene Discovery to Clinical Application



O'Donnell and Nabel: N Engl J Med 365:2098, 2011

- Facebook didn't exist yet
- Twitter was still a sound
- Cloud was still in the sky
- 4G was a parking space
- “applications” were what you sent to college
- LinkedIn most people thought it was a prison
- Big Data was a good name for a rap star
- Skype, for most people, was a typographical error.





